INT329566

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.37
First Reported 2010
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 4
Total Number 6
Disease Relevance 2.05
Pain Relevance 0.33

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Ccl4) extracellular region (Ccl4)
Ccl4 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Inflammatory mediators 2 98.72 Very High Very High Very High
cytokine 16 98.48 Very High Very High Very High
Inflammation 34 98.08 Very High Very High Very High
fibrosis 18 78.72 Quite High
depression 3 5.44 Low Low
ischemia 3 5.00 Very Low Very Low Very Low
adenocard 3 5.00 Very Low Very Low Very Low
Angina 3 5.00 Very Low Very Low Very Low
Pain 3 5.00 Very Low Very Low Very Low
anesthesia 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Apoptosis 19 99.64 Very High Very High Very High
INFLAMMATION 36 98.72 Very High Very High Very High
Disorder Of Lipid Metabolism 6 93.56 High High
Body Weight 7 84.24 Quite High
Necrosis 16 79.44 Quite High
Stress 12 79.28 Quite High
Fibrosis 11 78.72 Quite High
Fatty Liver 20 75.00 Quite High
Hepatotoxicity 42 73.08 Quite High
Injury 34 72.12 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Natansnin treatment significantly decreased the levels of CCl4 induced apoptotic proteins and inflammatory mediators.
Negative_regulation (decreased) of Gene_expression (levels) of CCl4 associated with inflammatory mediators and apoptosis
1) Confidence 0.37 Published 2010 Journal BMC Pharmacol Section Abstract Doc Link PMC2967507 Disease Relevance 0.80 Pain Relevance 0.10
Administration of L-carnitine or/and coenzyme Q10 (prior to CCl4 injection) significantly decreased hepatic total LDH activity compared to CCl4 control group as shown in Table 3.
Negative_regulation (decreased) of Gene_expression (injection) of CCl4
2) Confidence 0.36 Published 2010 Journal Scientia Pharmaceutica Section Body Doc Link PMC3007612 Disease Relevance 0 Pain Relevance 0
L-carnitine or/and coenzyme Q10 (prior to CCl4 injection) significantly decreased hepatic LPO level.
Negative_regulation (decreased) of Gene_expression (injection) of CCl4
3) Confidence 0.36 Published 2010 Journal Scientia Pharmaceutica Section Body Doc Link PMC3007612 Disease Relevance 0.29 Pain Relevance 0.04
Administration of any one of the three compounds prior to CCl4 injection) significantly decreased in all mentioned parameters compared to CCl4 control group as shown in Table 2.
Negative_regulation (decreased) of Gene_expression (injection) of CCl4
4) Confidence 0.36 Published 2010 Journal Scientia Pharmaceutica Section Body Doc Link PMC3007612 Disease Relevance 0 Pain Relevance 0
-Toc + CCl4 and T3 mix + CCl4 groups was decreased in comparison with the CCl4 group.
Negative_regulation (decreased) of Gene_expression (groups) of CCl4
5) Confidence 0.35 Published 2010 Journal Journal of Clinical Biochemistry and Nutrition Section Abstract Doc Link PMC2933434 Disease Relevance 0.48 Pain Relevance 0.10
-Toc + CCl4 and T3 mix + CCl4 groups was decreased in comparison with the CCl4 group.
Negative_regulation (decreased) of Gene_expression (groups) of CCl4
6) Confidence 0.35 Published 2010 Journal Journal of Clinical Biochemistry and Nutrition Section Abstract Doc Link PMC2933434 Disease Relevance 0.48 Pain Relevance 0.10

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox